Cardiac dose is a predictor of survival after chemoradiation for locally advanced lung cancer; however, its effect on survival after stereotactic body radiotherapy has not been adequately studied. We analyzed the cardiac doseevolume metrics and survival for 102 patients who had undergone lung stereotactic body radiotherapy. No cardiac dose metric was associated with survival, and no acute cardiac toxicity was identified, despite extremely high doses to small volumes of the heart in some cases. Introduction: Recent analyses have identified cardiac dose as an important predictor of overall survival (OS) after chemoradiation for locally advanced nonesmall-cell lung cancer (NSCLC). However, the survival influence of the cardiac dose after stereotactic body radiotherapy (SBRT) is unknown. We performed a doseevolume histogram (DVH) analysis of patients treated with SBRT for early stage NSCLC to examine survival and cardiac toxicity. Materials and Methods: We reviewed the medical records of patients who had undergone SBRT for early-stage NSCLC from June 2007 to June 2015 and documented the cardiac DVH parameters, including the maximum and mean dose and percentage of volume receiving >5, >10, >20, and >30 Gy (V5, V10, V20, and V30, respectively). The biologically effective doses and 2-Gy equivalent doses were also calculated. The DVH parameters were assessed as predictors of OS using Cox regression analysis. Results: We identified 102 patients with 118 treated tumors. At a median follow-up period of 27.2 months (range, 9.8-72.5 months), the 2-year OS estimate was 70.4%. The cardiac DVH parameters were as follows: maximum dose, median, 14.2 Gy (range, 0.3-77.8 Gy); mean dose, median, 1.6 Gy (range, 0-12.6 Gy); and V5, median, 8.7% (range, 0%-96.4%). We identified no correlation between OS and any cardiac dose parameter. No patient developed acute (within 3 months) cardiac toxicity. Four patients died of cardiac causes; all had had preexisting heart disease. Conclusion: In our cohort, cardiac dose was not a predictor of OS after lung SBRT, despite a subset of patients receiving high maximum cardiac doses. The findings from our limited cohort showed that high doses to small volumes of the heart appear safe. Analyses of larger patient cohorts with longer follow-up durations are needed to better delineate the safe cardiac DVH constraints for SBRT.
Introduction
Stereotactic body radiotherapy (SBRT) has emerged as a standard of care for early-stage, medically inoperable, nonesmall-cell lung cancer (NSCLC), providing 3-year in-field control of > 90% in prospective trials. 1, 2 Early studies reported elevated risks associated with SBRT over 3 fractions to centrally located tumors (defined as within a 2-cm margin of the proximal bronchial tree or directly abutting or overlapping the mediastinal pleura). 3 Subsequent studies using modestly protracted regimens of 50 to 60 Gy in 4 to 8 fractions have generally shown acceptable toxicity and good tumor control. [4] [5] [6] Toxicity studies evaluating the risks of SBRT have largely focused on the proximal bronchial tree, with rare treatmentassociated fatalities resulting from hemoptysis or postobstructive pneumonia. [6] [7] [8] Fewer studies have focused on other central structures, in particular, the heart. The risks of radiation doses to the heart have long been understood in the context of patients treated for breast cancer and lymphoma, 9, 10 with larger fields and relatively modest doses to large swaths of the heart leading to long-term cardiac disease years to decades later in often young patients with a relatively good oncologic prognosis. The role of the cardiac dose in lung cancer treatment was largely ignored until a recent secondary analysis from the phase III Radiation Therapy Oncology Group (RTOG) 0617 trial identified cardiac doseevolume metrics as major predictors of survival after concurrent chemoradiation for locally advanced NSCLC. An increased percentage of the volume of heart receiving 5 Gy (V5) and 30 Gy (V30) was strongly associated with a greater risk of death.
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The cardiac dosimetry of SBRT is markedly different from that typically found in stage III disease, with the potential for small volumes of the heart to receive high biologically effective doses (BEDs) but typically lower mean and integral doses to the heart owing to smaller treatment volumes. Furthermore, the patient population treated with lung SBRT is typically medically inoperable, with substantial pulmonary, cardiac, or other comorbidities. These patients are also often older on average than the cohorts undergoing chemoradiation for locally advanced disease. These patients' preexisting cardiac disease could theoretically predispose them to an increased risk of radiation-induced cardiotoxicity. No previous studies have specifically evaluated the role of cardiac dosimetry on survival after SBRT for NSCLC. We conducted a retrospective survival analysis of a large cohort of patients who underwent SBRT for early-stage NSCLC at a single institution, with a detailed cardiac doseevolume histogram (DVH) analysis to assess the effect of cardiac doseevolume metrics on survival and cardiac toxicity.
Materials and Methods

Patients
After institutional review board approval, the medical records of all patients who had undergone SBRT for early-stage NSCLC from June 2007 to June 2015 at the University of California, Davis, were retrieved and reviewed. The eligible patients had a retrievable electronic treatment plan with a DVH and a minimum follow-up period of 6 months or until death. The standard follow-up protocol included history, physical examination, and computed tomography (CT) of the chest every 3 months the first year after treatment, every 4 to 6 months the second year after treatment, and every 6 to 12 months thereafter until 5 years after treatment. The treatment and disease parameters and the interval to the last followup visit or death were recorded. The cause of death (cardiac or noncardiac) was identified from the clinic and hospitalization notes. Cardiac events after SBRT were identified from the follow-up notes, primary care visits, cardiology visits, and hospitalization records and were graded using the Common Terminology Criteria for Adverse Events, version 4.03. Only grade 3 cardiac events were captured owing to challenges in identifying lower grade cardiac events reliably from the available records. Acute cardiac events were defined as those occurring within 3 months after SBRT.
Radiotherapy
CT simulation was performed with the patients immobilized in the supine position using either the Elekta body frame (Elekta AB, Stockholm Sweden) or a long vacuum-lock bag on the Phillips Brilliance Big Bore 16-slice scanner (Royal Philips Electronics, Amsterdam, The Netherlands) with a 2-mm slice thickness. Simulation was performed with abdominal compression using either a plate or belt, and fluoroscopic assessment was performed to ensure the diaphragmatic excursion was limited to 1 cm. After December 2010, a 10-phase, 4-dimensional CT (4DCT) scan was obtained, in addition to a free-breathing CT scan, and the use of abdominal compression with fluoroscopic verification was continued. The primary tumor was contoured using lung windows. An internal target volume was generated using the 10-phase 4DCT scan for the patients with 4DCT simulation. An additional 5-mm planning target volume (PTV) margin was added for daily setup error after 4DCT simulation, and a 10-mm craniocaudal margin was used for patients without 4DCT simulation. The treatment plans were generated using Phillips Pinnacle treatment planning software (Royal Philips Electronics). Heterogeneity corrections Cardiac Dose and Survival After SBRT using a superposition/convolution algorithm were applied starting in March 2011; cases before March 2011 were calculated without heterogeneity correction. Of the tumors, 45 were treated using static noncoplanar beams, 30 using fixed beam, intensity modulated radiotherapy, and 43 using volume modulated arc therapy. The median prescribed dose was 50 Gy (range, 40-60 Gy) in a median of 4 fractions (range, [3] [4] [5] [6] [7] [8] . The cardiac constraints were individualized for each case and depended on tumor proximity to the heart; however, typically, the maximum point doses were limited to 105% of the prescription dose when the PTV overlapped the cardiac contour, and the volumetric doses were kept as low as reasonably achievable. Treatment was delivered using an Elekta Synergy (Elekta AB). Image guidance was performed using onboard kilovoltage cone beam CT imaging, with 3-dimensional anatomy matching to the planning CT scan. Fluoroscopy was assessed before each fraction to ensure the diaphragmatic excursion was limited to 1 cm. The DVH was retrieved and reviewed for each patient. The cardiac contour was reviewed and edited, if necessary. Consistent cardiac contouring was applied for each case in accordance with the RTOG 1106 Atlases for Organs at Risk and extended from the inferior aspect of the pulmonary artery cranially to the apex caudally. 12 The cardiac maximum dose, mean dose, V5, V10, and V20 were retrieved for each case. Rigid registration was used to generate a cumulative DVH for patients with multiple treatment courses.
Statistical Analysis
OS was assessed using the Kaplan-Meier method. To account for fractionation, we converted all maximum and mean cardiac doses to the BED, assuming an a/b ratio of 2 for the heart, 13,14 with conversion to an equivalent dose in 2-Gy fractions (EQD2/2) using the linear quadratic model. Both unconverted and converted values were analyzed. The influence of each cardiac DVH parameter on survival was assessed using a Cox regression model, with radiation dose as a continuous variable. OS for the cohort as a whole and for the patient cohorts with a cardiac maximum dose BED greater than and less than the median, respectively, were estimated using the Kaplan-Meier method.
Results
We reviewed the medical records of 118 patients treated with 1 courses of SBRT for early-stage NSCLC. Nine patients who had been lost to follow-up within 6 months of treatment were excluded. Also, 2 patients who had undergone previous conventionally fractionated radiotherapy to the lung and 5 patients who had 1 SBRT plans that could not be retrieved were excluded, leaving 102 eligible patients. The median age was 76.3 years (range, 48.9-93.1 years), including 46 men and 56 women. The patients underwent SBRT to 118 tumors, with a median prescription dose of 50 Gy (range, 40-60 Gy). We included 13 patients treated for 2 synchronous (n ¼ 8) or metachronous (n ¼ 5) primary tumors. Thirtytwo patients had 1 tumor classified as central using the RTOG Figure 1A) . The patient and treatment characteristics are outlined in Table 1 Table 2 , and the DVH statistics with all doses converted to BED 2 and EQD2/2 are listed in Table 3 . Our analysis yielded no statistically significant correlation between OS and any evaluated cardiac dose parameter (P > .05 for all). The OS curves for patients with a cardiac point maximum BED greater and less than the median are shown in Figure 1B . Thirteen patients (13%) had insufficient follow-up records available to confirm the presence or absence of grade 3 cardiac events during the entire follow-up period. No acute (defined as within 3 months after SBRT) cardiac toxicity was identified in any patient. Among the 89 patients with sufficient follow-up data to determine the occurrence of cardiac events, 10 (11%) experienced a grade 3 cardiac event, including 4 patients (4.5%) who died of cardiac causes (congestive heart failure in 3 patients and cardiac arrest in 1). All had had preexisting cardiac disease. An additional 6 patients developed grade 3 cardiac events, including myocardial infarction in 1 and chest pain leading to hospitalization and catheterization and/ or stent placement in 5. Of the 4 patients with a cardiac cause of death, 3 had DVH parameters less than the median for the cohort, and the median point maximum dose to the heart (9.4 vs. 13.7 Gy), median BED point maximum (19.4 Gy 2/2 vs. 32.7 Gy 2/2 ), and median cardiac mean BED (0.4 Gy 2/2 vs. 1.0 Gy 2/2 ) were all lower among patients with cardiac events than among those without cardiac events. DVH statistics for the four patients with a cardiac cause of death are outlined in Table 4 .
Discussion
Cardiac toxicity is a well-studied and feared complication after radiotherapy for Hodgkin's disease, left-sided breast cancer, and other malignancies that can result in significant radiation to the heart. Until the report of RTOG 0617, the cardiac risks after radiation for lung cancer were typically discounted in the face of a malignancy with poor survival. However, the RTOG 0617 data demonstrated a remarkable effect on survival from cardiac dosimetry, specifically the heart V5 and V30, despite a relatively modest median follow-up period of only 22.9 months. 11 These data suggest that the cardiac dose can affect survival within 2 years of treatment, at least with the doses received during concurrent chemoradiation for locally advanced NSCLC. However, similar studies specific to early-stage lung cancer treated with SBRT are lacking. The dosimetry of lung SBRT is markedly different from that encountered when treating locally advanced disease, with the potential for very high maximum point doses for targets adjacent to the heart but typically lower mean and volumetric parameters owing to the small targets and highly conformal planning. The patient population that undergoes SBRT is typically medically inoperable and, hence, expected to have a greater rate of significant comorbid cardiac disease compared with patients with locally advanced disease fit enough to tolerate concurrent chemoradiation. Although survival from stage I lung cancer is markedly superior to that of locally advanced disease. In our cohort, we identified a cardiac maximum point > 200 Gy 2/2 in several patients when converted to EQD2/2, markedly greater than those achieved with conventionally fractionated radiotherapy. However, the mean doses, V20, and V30 were typically low. Cardiac Dose and Survival After SBRT
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Previous studies that focused on SBRT for centrally located tumors identified an increased risk of toxicity, in particular, central airway injury 3,7 but did not identify an excess of cardiac deaths. An early and widely cited dose escalation study using a 3-fraction regimen from Indiana University identified a central tumor location (within 2 cm of the proximal bronchial tree) as a significant risk factor for high-grade toxicity. 3 One of the fatalities attributed to SBRT in that study was a fatal pericardial effusion. 3 However, no cardiac dosimetry was provided for that case. RTOG 0813, a prospective phase I/II evaluation of 5-fraction SBRT for centrally located, early-stage lung cancer allowed cardiac maximum doses of 105% of the prescription dose and suggested, but did not mandate, limiting the volume of heart receiving 32 Gy to < 15 cm 3 .
With these constraints, no grade 4 to 5 cardiac toxicity was described in the initial presentation of results, although the final results in full manuscript form are eagerly awaited. 6, 15 No published studies have yet specifically focused on the correlation between the cardiac dose and survival among patients undergoing SBRT for early-stage lung cancer. A small, retrospective study evaluated changes in cardiac fluorine-18 fluorodeoxyglucose uptake in the heart as a possible surrogate for myocardial injury after SBRT for tumors close to the heart. The investigators identified increased fluorine-18 fluorodeoxyglucose uptake in the heart when > 5 cm 3 of the heart received 20 Gy. 16 However, these findings have not been validated in larger studies. Our major finding in the present study was that the cardiac dose was not a predictor of OS in our patient population after SBRT for early-stage NSCLC. This was true for each cardiac DVH parameter, including the mean dose, maximum dose, V5, V10, V20, and V30. Although the mean cardiac dose was generally extremely low, consistent with the dosimetry of SBRT, a subset of patients had a high maximum cardiac EQD2/2 > 80 Gy or even > 150 Gy. Moreover, of the patients who died of known cardiac causes, all had had preexisting cardiac disease, and 3 of the 4 had had cardiac dose parameters less than the median of the population as a whole. We also analyzed grade 3 cardiac events during the follow-up period and found no correlation between the occurrence of cardiac events and cardiac dose. The present analysis was subject to the limitations of retrospectively identifying cardiac events from the medical records and from a lack of mandated follow-up cardiac testing, such as routine stress testing, echocardiography, or electrocardiography. However, in aggregate, our results suggest that delivery of high radiation doses to small volumes of the heart is relatively safe.
The present study had notable limitations. Given the significant medical comorbidities in the medically inoperable population, competing causes of death could have obscured a survival effect. The causes of death among the cohort varied and included metastatic disease, respiratory failure, and other primary neoplasms. In addition, the cause of death was not always clearly noted in the patient's electronic health record, in particular, for the long-term (> 5-year) survivors. Our median follow-up period of 27.2 months for the surviving patients might have been insufficient to detect an increase in cardiac deaths in this patient population. Our population of 102 patients might also have been too small to detect a subtle influence from the cardiac dose. Contouring of and dose tracking to specific cardiac substructures might also prove useful in understanding the effect of high radiation doses to small volumes of the heart. Our patients were treated with a range of fractionation schedules, from 3 to 8 sessions, and the linear quadratic model was used to convert to BEDs and EQD2/2. However, the applicability of the linear quadratic model from large fraction sizes has been questioned, 17 and the exact a/b ratio to use for calculations is poorly defined. Nevertheless, in the absence of a clearly more robust, validated method of comparing fractionation schedules, we reported the actual delivered dose, BED, and EQD2/2. Finally, early plans were generated without heterogeneity corrections, leading to possible moderate errors in the calculated dose in this patient subset.
Future studies should focus on a larger patient cohort with a longer follow-up period to better delineate the safe cardiac DVH constraints for SBRT and should examine the cardiac substructures, in addition to the cardiac dose as a whole.
Conclusion
High radiation doses to small volumes of the heart appear relatively safe in the medically inoperable population undergoing SBRT for NSCLC. This low rate of cardiac toxicity and death might be attributable to the typically low mean cardiac doses achieved in our cohort (median, 1.6 Gy), in keeping with the conformal dosimetry and typically small targets of SBRT. Our analyses did not identify a cardiac DVH parameter that predicted survival after lung SBRT. Our current institutional approach of limiting the point maximum doses to < 105% of the prescription dose and limiting the volumetric constraints to "as low as reasonably achievable" did not appear to result in an excess of early cardiac toxicity. Larger analyses with longer follow-up periods are needed.
Clinical Practice Points
The effect of cardiac doseevolume parameters on survival after SBRT for early-stage lung cancer has not been well studied. In our cohort, the cardiac dose metrics, including the maximum and mean doses and V5, V20, and V30 were not predictive of survival. No acute cardiac toxicity was identified in any patient in our cohort. With a median follow-up duration of 27.2 months, cardiac death occurred in 4 patients with preexisting cardiac disease; an additional 6 nonfatal cardiac events were identified. Our doseevolume analysis identified a subset of 13 patients with an EQD2 > 80 Gy without cardiac fatality. Further analyses should be performed on larger cohorts of patients, because our population might not have been large enough to identify a small survival decrement associated with a high cardiac dose.
